Quantcast

Latest Ipilimumab Stories

2008-08-12 12:00:34

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase 2A clinical trial is...

2008-08-07 12:00:18

Medarex has announced the allowance of an investigational new drug application filed with the FDA for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. The open-label, multi-dose, dose-escalation Phase I clinical trial is expected to enroll up to 46 patients with selected advanced or recurrent solid tumors. This trial is designed to establish and...

2008-08-05 09:00:13

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. MDX-1105 is a fully human antibody that targets the PD-L1 pathway to promote enhanced T-cell...

2008-08-01 18:00:08

Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the second quarter ended June 30, 2008. The net loss for the quarter ended June 30, 2008, was $2.8 million ($0.03 per fully diluted share), compared to a net loss of $1.9 million ($0.03 per fully diluted share) for the corresponding period in 2007. The company ended the quarter with approximately $165.5 million in cash, cash equivalents and short-term investments. This includes the $50.0 million payment received from Takeda...

2008-07-16 06:00:13

By Annette Wells By ANNETTE WELLS REVIEW-JOURNAL Randy Irwin is the ultimate guinea pig. He's the first to try out an experimental treatment by New Jersey- based Medarex for kidney cancer to determine whether it works and to observe possible side effects. Hopes were that his tumor would shrink or disappear - or at the very least remain in check - because of the treatment. But earlier this month the 50-year-old Las Vegas resident learned that, after three treatments in six weeks,...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related